title: Does interim PET increase the value of ABVD in advanced-stage Hodgkin lymphoma?
authors.affiliation: Department of Research, Innovation and Statistics, A. Lacassagne Cancer Centre, Nice, France. Electronic address: andreagallamini@gmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Gallamini
authors.affiliation: Department of Radiology, Division of Nuclear Medicine, Mount Sinai Medical Center, New York, USA.
authors.forename: L
authors.initials: L
authors.lastname: Kostakoglu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001761:Bleomycin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D049268:Positron-Emission Tomography; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D014057:Tomography, X-Ray Computed; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D005047:Etoposide; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone